Unfortunately that linked article is guilty of the 'misinformation' that's been plaguing Provenge regarding it's survival rates. Stating "average" rather than "median". The interpretation of which paints Provenge (wrongly) in a less than ideal light.
IMO, this seems to be the most significant issue with the poorly perceived cost/benefit ratio.
Hopefully (when the time comes) Prima release PR friendly efficacy stats that close the loop for the layperson and remove the possibility for misinterpretation.
Unfortunately that linked article is guilty of the...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.3¢ |
Change
0.003(0.74%) |
Mkt cap ! $501.1M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 34.8¢ | 33.5¢ | $159.0K | 463.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 76275 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 314252 | 15 |
View Market Depth
| Last trade - 13.53pm 29/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |